Difference between revisions of "Team:JNFLS/Parts"

Line 8: Line 8:
 
<h2>1.Part Table</h2>
 
<h2>1.Part Table</h2>
 
<p>The parts we submitted are listed in the table below.</p>
 
<p>The parts we submitted are listed in the table below.</p>
<img class="medium" src="https://static.igem.org/mediawiki/2017/4/42/JNFLS-Parts-1.png" />
+
<table>
 +
<tr><th>Part Number</th><th>Name</th><th>Type</th><th>Length</th><th>Description</th></tr>
 +
<tr><td><a href="http://parts.igem.org/Part:BBa_K2358000">BBa_K2358000</a></td><td>fdhF promoter</td><td>Regulatory</td><td>99</td><td>Hypoxia-inducible promoter</td></tr>
 +
<tr><td><a href="http://parts.igem.org/Part:BBa_K2358001">BBa_K2358001</a></td><td>fdhF inducible GFP device</td><td>Device</td><td>984</td><td>fdhF promoter controling GFP expression device</td></tr>
 +
<tr><td><a href="http://parts.igem.org/Part:BBa_K2358002">BBa_K2358002</a></td><td>TAT</td><td>Coding</td><td>309</td><td>Trans-Activator of Transcription</td></tr>
 +
<tr><td><a href="http://parts.igem.org/Part:BBa_K2358004">BBa_K2358004</a></td><td>hTERT</td><td>Regulatory</td><td>765</td><td>tumor-specific promoter</td></tr>
 +
<tr><td><a href="http://parts.igem.org/Part:BBa_K2358005">BBa_K2358005</a></td><td>survivin</td><td>Regulatory</td><td>980</td><td>tumor-specific promoter</td></tr>
 +
</table>
 +
<em style="text-align:center;">Table 1 parts information we submitted.</em>
 
<h2>2.Functions of the Parts</h2>
 
<h2>2.Functions of the Parts</h2>
 
<p>Both BBa_K2358000 and BBa_K2358001 (composed of BBa_K2358000 and BBa_E0840) are related with hypoxia, and we detected the start efficiency of the hypoxia inducible promoter. With the culture time passed, oxygen partial pressure decreased, and down to below zero quickly. Since the instrument can not detect the value below zero, we used the increasing of CO2 partial pressure to represent the decreasing of O2 partial pressure in the experiment.</p>
 
<p>Both BBa_K2358000 and BBa_K2358001 (composed of BBa_K2358000 and BBa_E0840) are related with hypoxia, and we detected the start efficiency of the hypoxia inducible promoter. With the culture time passed, oxygen partial pressure decreased, and down to below zero quickly. Since the instrument can not detect the value below zero, we used the increasing of CO2 partial pressure to represent the decreasing of O2 partial pressure in the experiment.</p>

Revision as of 14:23, 31 October 2017

JNFLS

Parts

We had devoted ourselves to explore a new method for treating colon cancer. It is well known that the oxygen partial pressure of solid tumor cells is very low, compared with normal cells. So we chose the hypoxia-induced promoter fdhF as the center part in our project.

1.Part Table

The parts we submitted are listed in the table below.

Part NumberNameTypeLengthDescription
BBa_K2358000fdhF promoterRegulatory99Hypoxia-inducible promoter
BBa_K2358001fdhF inducible GFP deviceDevice984fdhF promoter controling GFP expression device
BBa_K2358002TATCoding309Trans-Activator of Transcription
BBa_K2358004hTERTRegulatory765tumor-specific promoter
BBa_K2358005survivinRegulatory980tumor-specific promoter
Table 1 parts information we submitted.

2.Functions of the Parts

Both BBa_K2358000 and BBa_K2358001 (composed of BBa_K2358000 and BBa_E0840) are related with hypoxia, and we detected the start efficiency of the hypoxia inducible promoter. With the culture time passed, oxygen partial pressure decreased, and down to below zero quickly. Since the instrument can not detect the value below zero, we used the increasing of CO2 partial pressure to represent the decreasing of O2 partial pressure in the experiment.

BBa_K2358002 is a regulatory protein that drastically enhances the efficiency of viral transcription. The protein is released by infected cells in culture, and is found in the blood of HIV-1 infected patients. It also can be absorbed by cells that are not infected with HIV, and can act directly as a toxin producing cell death via apoptosis in uninfected bystander cells. For more details, please refer to the results.

BBa_K2358004 and BBa_K2358005 are tumor-specific promoters. They can only start gene expression in tumor and embryonic tissues. It is closely related to the proliferation and infiltration of tumor cells.